Cutia Therapeutics (HK:2487) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cutia Therapeutics has disclosed additional details on the allocation of the HK$392.7 million net proceeds from its global offering, as per Hong Kong Stock Exchange rules. The funds are earmarked for various R&D activities, local production, and technology development, with a significant portion still unutilized as of the end of 2023. These investments aim to support the company’s core and key products development, with a timeline extending up to 2029 for full utilization.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.